Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Pfizer-Allergan combo would comprise 100+ sites and post-Wyeth level headcount

12-Nov-2015 - Pfizer’s manufacturing network would stretch beyond 100 sites if a merger deal with Allergan is reached.

Unilife undecided on takeover plans; gives December 31 deadline

10-Nov-2015 - Unilife CEO Alan Shortall yesterday confirmed the drug delivery company is still “receiving interest from several parties under the strategic review process” and set a deadline of December 31 to...

Acquisitions drive AMRI’s ambition to become a ‘billion dollar’ CDMO

09-Nov-2015 - AMRI attributed recent M&A activity to passing the $100m (€93m) quarterly sales milestone, reporting high double-digit growth across its API and small-scale manufacturing divisions.

CPhI Worldwide 2015

Rush to acquire ex-pharma sites means survival of the biggest for CMOs

22-Oct-2015 - As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say...

CPhI Worldwide 2015

After the M&A bubble bursts: the four types of pharma firm to survive

21-Oct-2015 - An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future....


Sun Pharma eyes US ocular delivery expert

16-Sep-2015 - Indian generics company Sun Pharma has made a $48m (€42m) offer for US eye drug maker InSite Vision and its delivery platform.


Mylan targets Perrigo shareholders in latest generics mega-merger attempt

14-Sep-2015 - Mylan’s latest merger offer has been lambasted as “neither compelling, nor accretive” by Perrigo CEO Joseph Papa.

Horizon attempts $1.68bn hostile bid for Depomed

09-Sep-2015 - Horizon Pharma has renewed its efforts to take over pain and neurology firm Depomed for approximately $1.68bn (€1.5bn).

Cipla and Lannett add US plants as generics industry continues to consolidate

08-Sep-2015 - Cipla and Lannett have expanded their presence in the mid-sized US generics space through acquisitions totalling over $1.5bn.

‘Eat or be eaten;’ Mylan says Perrigo could be run as subsidiary

25-Aug-2015 - Mylan will run Perrigo as a wholly-owned subsidiary if it acquires between 50-80% of shares, the firm has clarified.

Pfizer’s $17bn Hospira deal set to close in September after US FTC clearance

24-Aug-2015 - Pfizer has received the final regulatory clearances to acquire Hospira but the US FTC says it must divests four sterile injectable products.

Merck & Co. plans over 2,500 manufacturing job cuts

17-Aug-2015 - An SEC filing reveals Merck has cut 29,160 jobs in five years, and over 2,500 more may be on the way.

Still no plans to resume manufacturing at former Ben Venue plant

17-Aug-2015 - The huge former Ben Venue injectables manufacturing plant in Ohio that became the center of controversy over drug shortages a few years ago remains off line, and the company that...

European pharma: CEO talent is the new measure of company calibre

30-Jul-2015 - Industry headhunters have picked their top CEOs in European pharma, saying the most successful investors keep chief execs in place even through hard times.  

Hikma buys B-I generics subsidiary, strengthens position in US market

28-Jul-2015 - Hikma says its $2.65bn acquisition of Roxane Laboratories will make it the sixth largest firm in the US generics space.


Teva to buy Allergan's generics biz for $40.5bn

27-Jul-2015 - Teva has struck a deal to buy Allergan’s generics business a week after its persistent attempts to acquire Mylan fell through.

Summit up as Celgene steps in to buy Merck & Co. campus

21-Jul-2015 - Celgene will take over a Merck & Co. facility in Summit, New Jersey which had been earmarked for closure.

News in brief

Torrent acquires Indian dermatological drugmaker Zyg

20-Jul-2015 - Torrent Pharma has added two facilities to its network through the acqusition of Zyg Pharma from the Encore Group.

Celgene boosting immune-inflammatory presence with $7.2bn Receptos deal

16-Jul-2015 - Celgene has shelled out $7.2bn (€6.6bn) to acquire Receptos which is developing an oral lymphocyte trafficking agent for multiple sclerosis and inflammatory bowel disorder.

'Outperform' Perrigo better off without Mylan, says analyst report

30-Jun-2015 - The proposed Perrigo merger with Mylan would be of no benefit to either firm in the “highly competitive” OTC sector, according to financial analysts BMO.

‘Record-breaking’ 2015 will see surge in pharma acquisitions

25-Jun-2015 - Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells 

Dealing with activist shareholders: Allergan CEO shares advice at BIO

18-Jun-2015 - Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.

UPDATE - Mylan demands a straightforward answer to whether Teva will make a legally binding exchange offer

Teva to Mylan: We will accomplish our 'strong and serious' takeover proposal

08-Jun-2015 - Teva has refuted accusations of “meddling” with Mylan’s business in the latest chapter of what one analyst says is a far from friendly, if not hostile takeover attempt.

Mylan to Teva: 'Stop meddling in our affairs'

02-Jun-2015 - Teva has been accused of "playing games" with Mylan by acquiring a 1.35% stake in the generics firm weeks after having a $40bn (EUR36bn) takeover bid snubbed....

EC competition concerns will not stop $17bn Sigma-Aldrich deal, says Merck

28-May-2015 - Merck KGaA is confident it will close the $17bn acquisition of Sigma-Aldrich in mid-2015 despite competition concerns from the European Commission (EC).

Key Industry Events


Access all events listing

Our events, Shows & Conferences...